Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Study Details
Study Description
Brief Summary
The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Venetoclax, Lenalidomide, Rituximab Rituximab 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12 Lenalidomide 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12. Venetoclax PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12. |
Drug: Venetoclax
PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
Drug: Lenalidomide
10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12.
Drug: Rituximab
375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12
|
Outcome Measures
Primary Outcome Measures
- Maximum Tolerated Dose (MTD) of the combination of lenalidomide, venetoclax and rituximab [42 Days]
Secondary Outcome Measures
- The proportion of patients with a Complete Response (CR) [Up to 4 Years]
Response will be assessed by the IRC (Immune-related Response Criteria) and the investigator on the basis of physical examinations and PET and CT scans using the Lugano 2014 criteria, taking into account results of bone marrow examinations for patients with bone marrow involvement at screening
- The proportion of patients that respond to treatment [Up to 4 Years]
The proportion of patients who achieve either partial or complete response by PET, CT and marrow. Response will be assessed by the IRC and the investigator on the basis of physical examinations and PET and CT scans using the Lugano 2014 criteria, taking into account results of bone marrow examinations for patients with bone marrow involvement at screening
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥18 years
-
Diagnosis of mantle cell lymphoma (MCL) established by histologic assessment
-
Laboratory, radiographic, physical exam findings and/or symptoms attributable to MCL
-
ECOG Performance Status (Eastern Cooperative Oncology Group Performance Status: an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death) less or equal to 2
-
All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program
-
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.
-
Men and Women of childbearing potential on appropriate contraception
-
Adequate organ function
-
Ability to understand and the willingness to sign a written informed consent.
-
Ability to swallow oral capsules/tablets
Exclusion Criteria:
-
Prior treatment for MCL with chemotherapy
-
Pregnant or breastfeeding women
-
Grade 2 or higher peripheral neuropathy
-
Known history of CNS (Central Nervous System) or leptomeningeal by MCL prior to study enrollment
-
Significant cardiovascular disease
-
Any condition that might significantly impair drug absorption as determined by the investigator
-
Uncontrolled active systemic fungal, bacterial, viral, or other infection, or intravenous anti-infective treatment within 2 weeks before first dose of study drug
-
History of stroke or intracranial hemorrhage within 6 months of 1st dose of study drug
-
Concurrent participation in another clinical trial
-
Subject has received a moderate or strong CYP3A inhibitor or inducer within 1 week prior to treatment initiation.
-
Psychiatric illness or social situations that would limit compliance with study requirements
-
Subject has known positivity to HIV
-
Active infection with Hepatitis B or C virus as determined by a detectable viral load on PCR.
-
Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to< 2 years.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | City of Hope Comprehensive Cancer Center | Duarte | California | United States | 91010 |
| 2 | University of Michgan Comprehensive Cancer Center | Ann Arbor | Michigan | United States | 48187 |
| 3 | The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | United States | 43210 |
Sponsors and Collaborators
- University of Michigan Rogel Cancer Center
Investigators
- Principal Investigator: Tycel Phillips, M.D., University of Michigan Rogel Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UMCC 2018.005
- HUM00140979